Innovent and GenFleet reach deal for KRAS inhibitor; TCR2 receives FDA's ODD on gavo-cel
Amgen became the first company in May to crack an undruggable target and earn approval for a KRAS inhibitor. Now, Innovent is looking to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
